Balyasny Asset Management
ACAD icon

Balyasny Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Balyasny Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,276,200
Closed -$19.5M – 1617
2018
Q2 		$19.5M Buy
1,276,200
+551,700
+76% +$9.84M 0.09% 316
2018
Q1 		$16.3M Buy
+724,500
New +$20.1M 0.07% 381
2016
Q2 		– Sell
-10,000
Closed -$280K – 1131
2016
Q1 		$280K Buy
+10,000
New +$218K ﹤0.01% 1027

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Balyasny Asset Management's ACAD Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 312,982 shares worth $6.97M. The stake represents 0.01% of the portfolio and ranks #1206 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ACAD as recently as Q4 2024.

Balyasny Asset Management first reported a position in ACAD in Q4 2016 and has held it in 18 quarters since. The position peaked at $26.1M in Q3 2018. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Balyasny Asset Management held 312,982 shares of Acadia Pharmaceuticals worth $6.97M as of Q1 2026.
  • Acadia Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1206 holding.
  • Balyasny Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 18 quarters since.
  • Balyasny Asset Management's Acadia Pharmaceuticals position peaked at $26.1M in Q3 2018.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.